[lemma=□] □ □
[lemma=exposure] □ □
[lemma=to] □ □
The concern for fetal harm following intrathecal DepoCyt administration is low , however , because systemic exposure to cytarabine is negligible . Since the transfer rate of cytarabine from the CSF to plasma is slow and the conversion of cytarabine to ara-U in the plasma is fast , systemic exposure to cytarabine was negligible following intrathecal administration of DepoCyt , 50 mg or 75 mg .